Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4-6 years old children
10.3760/cma.j.cn112338-20200409-00541
- VernacularTitle:4~6岁儿童接种麻疹-流行性腮腺炎-风疹联合减毒活疫苗加强免疫的免疫原性与安全性研究
- Author:
Yanhui XIAO
1
;
Shaoying CHANG
;
Shuang BAI
;
Runmao ZHAO
;
Jiehong WANG
;
Xueqiu WANG
;
Yunkai YANG
;
Yanli MA
;
Xiaoqin LIU
;
Linyun LUO
;
Min LYU
;
Haiping CHEN
Author Information
1. 中国生物技术股份有限公司，北京 100024
- Keywords:
Measles, mumps, and rubella combined vaccine;
Boost dose;
Immunogenicity;
Safety
- From:
Chinese Journal of Epidemiology
2021;42(6):1086-1091
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine (MMR) for children 4 to 6 years old.Methods:Children, aged 4 to 6 years old, had vaccinated with 1 dose of measles and rubella combined vaccine(MR) at the age of 8 months and 1 dose of MMR vaccine at 18-months, were recruited in Shanxi, Inner Mongolia, and Beijing, respectively. All children were assigned into 4, 5 and 6-year-old group. The children who met inclusion and exclusion criteria were vaccinated with 1 dose MMR vaccine, and were collected blood samples before vaccination and 35 to 42 d after the vaccination. During the study period, adverse events were collected at 30 min, 1 d, 2 d, 3 d, 4-12 d, and 13 to 42 days after vaccination. Serum was tested for IgG antibodies against measles, mumps and rubella. Geometric mean concentrations (GMC) of measles, mumps, and rubella antibodies were compared among groups by analysis of variance or non-parametric test. Seropositive rates and adverse event rates were compared among groups by Chi-square test or Fisher exact test.Results:A total of 500 children were included in immunogenicity analysis and 535 children were included in safety analysis. The overall adverse event rate was 20.37%, the most of severity for adverse events was mild. The rates of local and systemic adverse events were 0.37% and 20.00%, respectively. Symptoms of local adverse events were redness. The main systemic adverse events were fever, followed by cough, rash and runny nose. Received a dose of MMR vaccine for booster immunization, the seropositive rates of measles antibody, mumps antibody and rubella antibody were above 99% for all 3 age groups, and there was no significant difference between groups. There were significant differences in mumps antibody GMC among groups ( P=0.042), but no significant differences in measles and rubella antibodies GMC. Conclusion:The immunogenicity and safety of a boosted MMR vaccintion in children aged 4, 5 and 6 years were all similar good.
